within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX17_EnisamiumIodide;
model EnisamiumIodide 
   extends Pharmacolibrary.Drugs.ATC.J.J05AX17;

  annotation(Documentation(
    info ="<html><body><p>Enisamium iodide is an isonicotinic acid derivative used as an antiviral agent, primarily investigated for the treatment of influenza and, more recently, for COVID-19. It is commercialized in several countries in Eastern Europe and Asia as an over-the-counter medication, but it is not widely approved or used in Western countries.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed pharmacokinetic studies reporting actual parameter values (bioavailability, clearance, volume of distribution, etc.) of enisamium iodide in humans have been published as of June 2024.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end EnisamiumIodide;
